Published in Vaccine Weekly, November 2nd, 2011
"In the current study, an anti-AgI/II MAb reported in the literature to confer unexplained long term protection...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2011-11-02)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.